当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Fedrick Tyler
A vast range of extracellular and intracellular biopolymers, including polyamides, polysaccharides, polyphosphates, polyesters, proteinaceous compounds, and extracellular DNA, may be produced by bacteria, which are regarded as the primary cell manufacturers. Bacterial biopolymers are employed in pathogenicity and are appropriate for use in the pharmaceutical industry due to their wide range of physical and chemical characteristics. When these biopolymer compounds are created by non-pathogenic bacteria, they function as food additives or biomaterials, however when they are derived from pathogenic bacteria, they serve as significant virulence factors. Using synthetic biology to create novel biomaterials, there have been multidisciplinary researches looking at the molecular processes involved in the synthesis of bacterial biopolymers and the discovery of new antimicrobial drug targets.